Investors & News Veronica Oronos 4/24/23 Veronica Oronos 4/24/23 Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients Read More Veronica Oronos 2/20/23 Veronica Oronos 2/20/23 Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects Read More Veronica Oronos 5/30/22 Veronica Oronos 5/30/22 Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease Read More
Veronica Oronos 4/24/23 Veronica Oronos 4/24/23 Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients Read More
Veronica Oronos 2/20/23 Veronica Oronos 2/20/23 Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects Read More
Veronica Oronos 5/30/22 Veronica Oronos 5/30/22 Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease Read More
